Results 161 to 170 of about 2,752 (194)

Roflumilast, indacaterol maleate, and abiraterone acetate

Journal of the American Pharmacists Association, 2011
roflumilast Chronic obstructive pulmonary disease (COPD) is a progressive, irreversible lung disease that is often associated with chronic bronchitis or emphysema and is typically characterized by symptoms such as breathlessness, chronic cough, and excessive production of mucus.
Daniel A, Hussar, Jeanine, DePasquale
openaire   +2 more sources

Indacaterol once-daily is equally effective dosed in the evening or morning in COPD [PDF]

Respiratory Medicine, 2010
SummaryIndacaterol is a novel, inhaled, long-acting β2-agonist providing 24-h bronchodilation with once-daily (o.d.) dosing in patients with COPD.In this double-blind, incomplete block crossover study, patients with moderate-to-severe COPD were ...
D. Jadayel, Jadayel, D., Henley, M., C. Verkindre, B. Kramer, Jack, D., H. Magnussen, Kramer, B., R. Woessner, Woessner, R., D. Jack, Verkindre, C., Magnussen, H., M. Henley, Higgins, M., M. Higgins   +15 more
exaly   +2 more sources

The Design of the Indacaterol Molecule

2013
β2-Adrenoceptor agonists have been used as bronchodilators for the treatment of asthma and COPD for over a century. Throughout this period, β2-adrenoceptor agonists have continued to evolve to best meet the needs of the patient, with improvements having been made to the selectivity, route of administration and duration of effect.
Robin A. Fairhurst, Steven J. Charlton, Alexandre Trifilieff   +2 more
openaire   +1 more source

The Risks and Benefits of Indacaterol — The FDA's Review

New England Journal of Medicine, 2011
In July, the FDA approved Arcapta Neohaler (indacaterol maleate powder), a long-acting beta-agonist, at a daily dose of 75 μg for chronic obstructive pulmonary disease. Why was this dose selected, after the European Medicines Agency approved 150-μg and 300-μg doses?
Badrul A, Chowdhury, Sally M, Seymour, Theresa M, Michele, Anthony G, Durmowicz, Dongmei, Liu, Curtis J, Rosebraugh   +5 more
openaire   +2 more sources

Rapid enantiomeric separation of indacaterol by electrokinetic chromatography

Journal of Chromatography A
The first chiral methodology enabling the separation of indacaterol enantiomers was developed in this work by cyclodextrin-electrokinetic chromatography. Indacaterol (IND) is a chiral drug marketed as a pure enantiomer. Then, the separation and quantification of each enantiomer is of great importance for the quality control of pharmaceutical ...
María Luisa Marina Alegre, María Castro Puyana   +1 more
exaly   +3 more sources

Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation

Expert Opinion on Drug Metabolism & Toxicology, 2013
Indacaterol is a β2-agonist with a rapid onset of action and a bronchodilating effect that lasts for 24 h.This review considers indacaterol in chronic obstructive pulmonary disease patients, in whom it is rapidly absorbed into the systemic circulation with serum levels measurable after 5 min and Cmax being reached approximately 15 min post-dose.
CAZZOLA, MARIO, Calzetta, L, Page, C, Matera, M.   +3 more
openaire   +3 more sources

The effect of indacaterol during an acute exacerbation of COPD

Pulmonary Pharmacology & Therapeutics, 2013
Some clinical trials have suggested that the inhaled long-acting β2-agonists (LABAs) may be effective in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Since indacaterol, the first once-daily LABA to be developed for the regular treatment of COPD, exhibits fast onset of action and 24-h duration of ...
SEGRETI, ANDREA, Fiori, E, Calzetta, L, Sabatini, M, Segreti, V, ROGLIANI, PAOLA, CAZZOLA, MARIO   +6 more
openaire   +3 more sources

The Early Clinical Development of Indacaterol

2013
Indacaterol is a novel once-daily β2-adrenoceptor agonist developed for the treatment of obstructive airway diseases. While indacaterol is now approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in several countries worldwide, the early clinical development of indacaterol was conducted in both asthma and COPD patients.
Jutta Beier, Kai M. Beeh
openaire   +1 more source

Indacaterol for chronic obstructive pulmonary disease

2023
Therapeutics Letter 102 reviews indacaterol for obstructive pulmonary disease. Conclusions: The only single product dose of inhaled indacaterol approved in Canada is 75 µg. Doses of indacaterol higher than 75 µg were not significantly different in any clinically meaningful outcome measure as compared to lower doses.
openaire   +1 more source

Indacaterol Novartis/skyePharma.

Current opinion in investigational drugs (London, England : 2000), 2006
In collaboration with SkyePharma, Novartis is developing a multidose dry powder inhaler formulation of indacaterol, a long-acting beta2 agonist and bronchodilator, for the potential treatment of asthma and chronic obstructive pulmonary disease. In January 2006, Novartis expected phase III clinical trials to start in early 2006, with submission planned ...
openaire   +1 more source